Home › Esophageal Cancer › Massachusetts › Boston
Esophageal Cancer clinical trials in Boston, MA
23 studies for Esophageal Cancer are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
- Massachusetts General Hospital, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Recruiting
- Dana-Farber Cancer Institute, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RecruitingPhase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
RecruitingPhase 1
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
- Tufts Medical Center, Boston
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RecruitingPhase 2
- Massachusetts General Hospital (Data Collection Only), Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RecruitingPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecruitingPhase 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
RecruitingPhase 3
- Massachusetts General Hospital, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
Recruiting
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- Dana Farber Cancer Institute, Boston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RecruitingPhase 3
- Research Site, Boston
Serial MRI Scans During Radiation Therapy
Recruiting
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
RecruitingPhase 2
- Massachusetts General Hospital, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
RecruitingPhase 1
- Mass General Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Massachusetts General Hospital - Dana Farber, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- and 2 more
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
RecruitingPhase 1/2
- Massachusetts General Hospital, Boston
About Esophageal Cancer
Early esophageal cancer does not have symptoms. Factors that increase risk include heavy drinking and smoking. Learn how you can reduce your risk.
More about Esophageal Cancer on MedlinePlus
Esophageal Cancer trials in other cities
- Houston, TX36 studies
- New York City, NY22 studies
- Nashville, TN19 studies
- St. Louis, MO17 studies
- Pittsburgh, PA15 studies
- Los Angeles, CA15 studies
- Baldwin Park, CA14 studies
- Grand Rapids, MI14 studies
- Philadelphia, PA13 studies
- San Antonio, TX12 studies
- Dallas, TX11 studies
- Rochester, MN11 studies
Other studies in Boston
- Breast Cancer112 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)85 studies
- Metastatic Cancer63 studies
- Colorectal Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.